Acorda Appoints Peter S. Carbone Senior Vice President, Quality
February 04 2019 - 7:00AM
Business Wire
Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that
Peter S. Carbone has joined the Company as Senior Vice President,
Quality. Mr. Carbone will report to Ron Cohen, M.D., President and
CEO of Acorda and will be a member of the Company’s Leadership
Team.
In his role, Mr. Carbone will lead Acorda’s Quality Assurance
and Quality Control departments and manage all company-wide quality
initiatives, including the Quality Management System. In addition,
he will develop and maintain quality programs to ensure Acorda’s
compliance with guidelines of the U.S. Food and Drug Administration
(FDA) and other world-wide health authorities. Mr. Carbone will
manage teams in Acorda’s Ardsley, New York headquarters and its
Boston, Massachusetts manufacturing and development facilities.
“Peter brings to Acorda over 30 years of pharmaceutical and
industry experience in engineering, quality and technical
management,” said Dr. Cohen, “We are delighted to welcome him to
our leadership team. One of our top priorities is to continue to
the build upon the strong track record of success of our quality
teams as we manufacture and commercialize INBRIJA and develop other
products in our pipeline. Peter’s leadership will be critical to
these efforts.”
Before joining Acorda, Mr. Carbone was the Vice President of
Quality Solids Americas & Special Technologies at Novartis,
responsible for the oversight of eight manufacturing facilities in
North and South America and Europe, and for commercial Quality for
all Sandoz products distributed in the US.
“I am very excited to be joining Acorda. The approval of INBRIJA
is an important milestone for the Company and for patients, and I
look forward to partnering with the Company’s Quality teams to
maintain and build on the excellent systems they have developed,”
said Carbone.
Prior to joining Novartis, Mr. Carbone spent over two decades in
a variety of roles of increasing seniority at a number of
pharmaceutical companies, including Allergan, where he was the Vice
President of Biologics Quality, and Amgen, where he was the
Executive Director of Corporate Quality-Validation. He has a B.S.
in Chemical Engineering from Rensselaer Polytechnic Institute. He
is a previous member of the ISPE International Board of Directors,
the ISPE Quality Metrics Steering Committee and PhRMA GQMC.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function and
improve the lives of people with neurological disorders. INBRIJA™
(levodopa inhalation powder) is approved for intermittent treatment
of OFF episodes in patients with Parkinson’s treated with
carbidopa/levodopa. INBRIJA utilizes Acorda’s innovative ARCUS®
pulmonary delivery system, a technology platform designed to
deliver medication through inhalation. Acorda also markets the
branded AMPYRA® (dalfampridine) Extended Release Tablets, 10
mg.
Forward-Looking Statement
This press release includes forward-looking statements. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects
should be considered forward-looking. These statements are subject
to risks and uncertainties that could cause actual results to
differ materially, including: we may not be able to successfully
market Inbrija or any other products under development; risks
associated with complex, regulated manufacturing processes for
pharmaceuticals, which could affect whether we have sufficient
commercial supply of Inbrija to meet market demand; third party
payers (including governmental agencies) may not reimburse for the
use of Inbrija or our other products at acceptable rates or at all
and may impose restrictive prior authorization requirements that
limit or block prescriptions; competition for Inbrija, Ampyra and
other products we may develop and market in the future, including
increasing competition and accompanying loss of revenues in the
U.S. from generic versions of Ampyra (dalfampridine) following our
loss of patent exclusivity; the ability to realize the benefits
anticipated from acquisitions, among other reasons because acquired
development programs are generally subject to all the risks
inherent in the drug development process and our knowledge of the
risks specifically relevant to acquired programs generally improves
over time; we may need to raise additional funds to finance our
operations and may not be able to do so on acceptable terms; the
risk of unfavorable results from future studies of Inbrija
(levodopa inhalation powder) or from our other research and
development programs, or any other acquired or in-licensed programs
; the occurrence of adverse safety events with our products; the
outcome (by judgment or settlement) and costs of legal,
administrative or regulatory proceedings, investigations or
inspections, including, without limitation, collective,
representative or class action litigation; failure to protect our
intellectual property, to defend against the intellectual property
claims of others or to obtain third party intellectual property
licenses needed for the commercialization of our products; and
failure to comply with regulatory requirements could result in
adverse action by regulatory agencies.
These and other risks are described in greater detail in our
filings with the Securities and Exchange Commission. We may not
actually achieve the goals or plans described in our
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in
this press release are made only as of the date hereof, and we
disclaim any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of
this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190204005199/en/
MEDIA:Gail Cohen(914) 326-5162gcohen@acorda.com
INVESTOR RELATIONS:Felicia Vonella(914)
326-5146fvonella@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Apr 2023 to Apr 2024